SC 13D/A 1 tm2028945-1_sc13da.htm SCHDULE 13D/A

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

SCHEDULE 13D  

  

 

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

 

Intellia Therapeutics, Inc.

(Name of Issuer)

 

COMMON STOCK, PAR VALUE $0.0001 PER SHARE

(Title of Class of Securities)

 

45826J105

(CUSIP Number)

 

Scott A. Brown
General Counsel and
Chief Administrative Officer
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-8000
 

With a copy to:

 

G. Scott Lesmes, Esq.

Hillary P. Daniels, Esq.
Morrison & Foerster LLP
2000 Pennsylvania Avenue NW, Suite 6000
Washington, D.C. 20006
(202) 887-1500

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

August 6, 2020

(Date of Event Which Requires Filing of this Statement)
 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-l(f) or 240.13d-l(g), check the following box. o

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 45826J105  
 
      1.     Names of Reporting Persons
 Novartis Institutes for BioMedical Research, Inc.  
 
    2.   

Check the Appropriate Box if a Member of a Group (See Instructions)   

 

        (a)    o  
        (b)    o  
 
    3.  

SEC Use Only  

 

     
    4.   Source of Funds (See Instructions)
 WC  
 
    5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  o  

 

 
  6.     Citizenship or Place of Organization
 Delaware  
 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With    		 7.     Sole Voting Power
 None  
 
8.     Shared Voting Power
4,352,295  
 
9.     Sole Dispositive Power
 None  
 
10.     Shared Dispositive Power
 4,352,295  
 
      11.   Aggregate Amount Beneficially Owned by Each Reporting Person
 4,352,295  
 
    12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o  

 

 
      13.   Percent of Class Represented by Amount in Row (11)
 7.4%*  
 
      14.     Type of Reporting Person (See Instructions)
 CO    
           

 

* This calculation is based on 58,740,613 shares of common stock, par value $0.0001 per share (“Common Stock”), outstanding as of July 31, 2020, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, filed by the Issuer with the Securities and Exchange Commission (“SEC”) on August 6, 2020.

 

2

 

 

CUSIP No. 45826J105    
     
      1.     Names of Reporting Persons
 Novartis AG    
     
      2.    

Check the Appropriate Box if a Member of a Group (See Instructions)    

 

        (a)    ¨  
        (b)    ¨  
     
      3.    

SEC Use Only

 

     
      4.     Source of Funds (See Instructions)
 AF    
     
      5.    

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ¨  

 

     
      6.     Citizenship or Place of Organization
 Switzerland    
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With    		 7.     Sole Voting Power
 None    
     
8.     Shared Voting Power
 4,352,295    
     
9.     Sole Dispositive Power
 None    
     
10.     Shared Dispositive Power
 4,352,295    
     
      11.     Aggregate Amount Beneficially Owned by Each Reporting Person
 4,352,295    
     
      12.    

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨  

 

     
      13.     Percent of Class Represented by Amount in Row (11)
 7.4%*    
     
      14.     Type of Reporting Person (See Instructions)
 CO, HC    
           

 

* This calculation is based on 58,740,613 shares of Common Stock outstanding as of July 31, 2020, as reported by the Issuer on its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, filed by the Issuer with the SEC on August 6, 2020.

 

3

 

 

Explanatory Note

 

This Amendment No. 4 (the “Amendment No. 4”) amends the statement on Schedule 13D originally filed by the Reporting Persons on May 11, 2016 and amended on December 14, 2017, March 23, 2018 and March 30, 2020 (the “Schedule 13D”). The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D.

 

Item 1.  Security and Issuer

 

Item 1 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

 

“This Statement on Schedule 13D relates to the common stock, par value $0.0001 per share (the “Common Stock”) of Intellia Therapeutics, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 40 Erie Street, Cambridge, Massachusetts 02139.”

 

Item 2. Identity and Background

 

Item 2 of the Schedule 13D is hereby amended such that all references to Schedule I contained within Item 2 and otherwise within the Schedule 13D shall refer to the Schedule I included in this Amendment No. 4.

 

Item 2(c) of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

 

“(c) NIBRI is a company organized under the laws of the State of Delaware and is a wholly-owned indirect subsidiary of Novartis. NIBRI is a research organization that works to discover innovative medicines that treat disease and improve human health.

 

Novartis is a corporation organized under the laws of Switzerland and is the publicly owned parent of a multinational group of companies specializing in the research, development, manufacturing and marketing of healthcare products, led by innovative pharmaceuticals and also including high-quality generic pharmaceuticals. Novartis is the 100% indirect owner of NIBRI.”

 

Item 5. Interest in Securities of the Issuer

 

Items 5(a) and (b) of the Schedule 13D are hereby amended and restated in their entirety to read as follows:

 

“(a)-(b) As of the date hereof, each of the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of 4,352,295 shares of Common Stock. Each Reporting Person has shared voting and dispositive power with the other Reporting Person.

 

Based on the 58,740,613 shares of Common Stock outstanding as of July 31, 2020, as reported by the Issuer on its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, filed by the Issuer with the SEC on August 6, 2020, the Common Stock held by the Reporting Persons constitutes 7.4% of the outstanding shares of Common Stock of the Issuer.

 

NIBRI is a wholly-owned indirect subsidiary of Novartis. Novartis, as the parent company of NIBRI, may be deemed to beneficially own all of the shares of Common Stock held directly by NIBRI.” 

 

4

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Pursuant to Rule 13d-1(k)(1)(iii) of Regulation 13D-G of the General Rules and Regulations of the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached statement is filed on behalf of each of them.

 

Dated: August 20, 2020

 

    NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.  
     
    By:   /s/ Scott A. Brown  
      Name:   Scott A. Brown  
        Title:   Authorized Signatory  
       
    NOVARTIS AG  
       
    By:   /s/ Christian Rehm

        Name:  

Christian Rehm

        Title:   Authorized Signatory  
               
    By:   /s/ Felix Eichhorn
        Name:  

Felix Eichhorn

        Title:   Authorized Signatory  

 

5

 

 

Schedule I

 

DIRECTORS AND EXECUTIVE OFFICERS OF

NOVARTIS AG AND NOVARTIS INSTITUTES FOR BIOMEDICAL
RESEARCH, INC.

 

DIRECTORS AND EXECUTIVE OFFICERS OF NOVARTIS AG

 

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis AG are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis AG and (ii) the business address of each director and executive officer of Novartis AG is Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland.

 

Name  Relationship to
Novartis AG		  Present Principal Occupation  Citizenship
Joerg Reinhardt, Ph.D.  Chairman of the Board of Directors  Chairman of the Board of Directors  German
          
Enrico Vanni, Ph.D.  Vice Chairman of the Board of Directors  Independent Director  Swiss
          
Nancy C. Andrews, M.D., Ph.D.  Director  Dean emerita, vice chancellor emerita for academic affairs, Duke University School of Medicine, US; Nanaline H. Duke Professor of Pediatrics, pharmacology and cancer biology, Duke University, US  American/Swiss
          
Ton Buechner  Director  Independent Director  Dutch/Swiss
          
Patrice Bula  Director  Executive vice president and head of strategic business units, marketing, sales, and Nespresso, Nestle SA, Switzerland  Swiss
          
Srikant Datar, Ph.D.       Director       Arthur Lowes Dickinson Professor, Harvard Business School, US; Faculty Chair of the Harvard Innovation Lab, US; Senior Associate Dean for University Affairs, Harvard Business School, US  American    

 

 

 

 

Elizabeth (Liz) Doherty       Director  Independent Director  British
          
Ann Fudge  Director       Independent Director  American    
          
Bridgette Heller  Director  Co-founder and Chief Executive Officer, Shirley Proctor Puller Foundation, US  American    
          
Frans van Houten       Director       Chief Executive Officer and chairman of the executive committee and the board of management, Royal Philips NV, Netherlands  Dutch    
          
Simon Moroney  Director  Independent Director  German/New Zealander
          
Andreas von Planta, Ph.D.       Director       Senior Counsel, Lenz & Staehelin, Switzerland  Swiss    
          
Charles L. Sawyers, M.D.       Director       Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, US; Professor of Medicine and of Cell and Developmental Biology, Weill Cornell Graduate School of Medical Sciences, US  American    
          
William T. Winters       Director       Chief Executive Officer and director of Standard Chartered PLC, UK  British, American    

 

 

 

 

Vasant (Vas) Narasimhan, M.D.       Member of the Executive Committee; Chief Executive Officer       Member of the Executive Committee; Chief Executive Officer       American    
          
Steven Baert       Member of the Executive Committee; Chief People and Organization Officer       Member of the Executive Committee; Chief People and Organization Officer       Belgian    
          
Bertrand Bodson  Member of the Executive Committee; Chief Digital Officer  Member of the Executive Committee; Chief Digital Officer  Belgian
          
James (Jay) Bradner, M.D.       Member of the Executive Committee; President, Novartis Institutes for BioMedical Research  Member of the Executive Committee; President, Novartis Institutes for BioMedical Research  American    
          
Harry Kirsch       Member of the Executive Committee; Chief Financial Officer  Member of the Executive Committee; Chief Financial Officer  German/Swiss    
          
Shannon Thyme Klinger  Member of the Executive Committee; Chief Legal Officer  Member of the Executive Committee; Chief Legal Officer  American    
          
Steffen Lang, Ph.D.  Member of the Executive Committee; Global Head of Novartis Technical Operations  Member of the Executive Committee; Global Head of Novartis Technical Operations    German/Swiss
          
Klaus Moosmayer, Ph.D.  Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer  Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer  German
          
Richard Saynor       Member of the Executive Committee; Chief Executive Officer, Sandoz  Member of the Executive Committee; Chief Executive Officer, Sandoz  British    
          
Susanne Schaffert, Ph.D.  Member of the Executive Committee; President, Novartis Oncology  Member of the Executive Committee; President, Novartis Oncology  German    
          
John Tsai, M.D.  Member of the Executive Committee; Global Head of Drug Development and Chief Medical Officer  Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer  American

 

Marie-France Tschudin       Member of the Executive Committee; President, Novartis Pharmaceuticals  Member of the Executive Committee; President, Novartis Pharmaceuticals  Swiss    
          
Robert Weltevreden  Member of the Executive Committee; Head of Novartis Business Services  Member of the Executive Committee; Head of Novartis Business Services  Dutch

 

 

 

 

 

DIRECTORS AND EXECUTIVE OFFICERS OF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

 

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis Institutes for BioMedical Research, Inc. (“NIBR”) are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis Institutes for BioMedical Research, Inc. and (ii) the business address of each director and executive officer for Novartis Institutes for BioMedical Research, Inc. is 250 Massachusetts Avenue, Cambridge, MA 02139, USA.

 

Name   Relationship to Novartis Institutes
for BioMedical Research, Inc. 		  Present Principal
Occupation 		  Citizenship
Joerg Reinhardt, Ph.D.  Chairman of the Board of Directors  Chairman of the Board of Directors, NIBR; Chairman of the Board of Directors; Novartis AG; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
Thomas Kendris  Director  President, Novartis Corporation; US Country President, Novartis Pharmaceuticals; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  American
          
Harry Kirsch  Director  Member of the Novartis AG Executive Committee; Chief Financial Officer, Novartis AG; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
James (Jay) Bradner, M.D.  Vice Chairman of the Board of Directors; President  Member of the Novartis AG Executive Committee; President of NIBR; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  American
          
Dimitris Agrafiotis  Chief Information Officer  Chief Information Officer, NIBR  American and Greek
          
Silvia Arber, Ph.D.  Senior Group Leader Musculoskeletal, FMI  Senior Group Leader Musculoskeletal, FMI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  Swiss

 

 

 

 

Evan Beckman, M.D.  Global Head Translational Medicine  Global Head Translational Medicine, NIBR  American
          
Tewis Bouwmeester, Ph.D.  Head DAx, CBT, NIBR Site Head Switzerland  Head DAx, CBT, NIBR Site Head Switzerland, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  Netherlands
          
Karin Briner, Ph.D.  Head, Chemistry  Head, Chemistry, NIBR  Swiss
          
Scott Brown  Vice President and General Counsel; Chief Administrative Officer; Secretary  Vice President and General Counsel; Chief Administrative Officer; Secretary, NIBR  American
          
Christian Bruns, Ph.D.  Global Head, ATI  Global Head, ATI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
Fenella Chisholm  Global Head People & Organization  Global Head People & Organization, NIBR  British
          
Stephen Cho, Ph.D.  Global Head, Portfolio Management  Global Head, Portfolio Management, NIBR  American
          
Shaun Coughlin  Global Head CVM  Global Head CVM, NIBR  American
          
Thierry Diagana, Ph.D.  Head NITD  Head NITD, One Health Plaza, East Hannover, NJ 07936  American
          
Ricardo Dolmetsch, Ph.D.  Global Head, Neuroscience  Global Head, Neuroscience, NIBR  American, British, Colombian
          
Glenn Dranoff, M.D.  Global Head, Exploratory Immuno-Oncology  Global Head, Exploratory Immuno-Oncology, NIBR  American
          
Jeffrey Engelman, M.D., Ph.D.  Oncology Disease Area Head  Oncology Disease Area Head, NIBR  American

 

 

 

 

Mairead Goetz  Global Head, NIBR SciOps  Global Head, NIBR SciOps  Irish
          
Philip Gotwals, Ph.D.  Global Head BD&L  Global Head BD&L, NIBR  American
          
Cynthia Grosskreutz, M.D., Ph.D.  Global Head Ophthalmology Diseases  Global Head Ophthalmology Diseases, NIBR,  American
          
Jerry Joyce  Institute Director, GNF  Institute Director, GNF, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121  American
          
Michaela Kneissel, Ph.D.  Global Head Musculoskeletal  Global Head Musculoskeletal, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  Austrian
          
En Li, Ph.D.  Head CNIBR  Head CNIBR, Novartis Shanghai Campus, 4218 Kinke Road, Pudong New Area, Shanghai, China 201203  American
          
Jeffrey Lockwood  Head, NIBR Communications  Head, NIBR Communications, NIBR  American
          
Vishal Patel, Ph.D.  Chief of Staff  Chief of Staff, NIBR  American
          
Thomas Pietzonka, Dr. sc. nat  Global Head Biotherapeutic and Analytical Tech  Global Head Biotherapeutic and Analytical Tech, NIBR, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  Swiss
          
Jeffrey Porter  Head Chemical Biology and Therapeutics  Head Chemical Biology and Therapeutics, NIBR  American
          
Revathi Rammohan  Chief Financial Officer and Head of Research Operations; Treasurer  Chief Financial Officer and Head of Research Operations; Treasurer, NIBR  British

 

 

 

 

Dirk Schuebeler, Ph.D.  Senior Group Leader, Musculoskeletal, FMI  Senior Group Leader, Musculoskeletal, FMI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
Alice Shaw, M.D., Ph.D.  Global Head Translational Clinical Oncology  Global Head Translational Clinical Oncology, NIBR  American
          
Jean Silveri  Global Head R&D IP  Global Head R&D IP, NIBR  American
          
Fiona Spence, Ph.D.  Global Head of Preclinical Safety  Global Head of Preclinical Safety, NIBR  United Kingdom
          
Wendi Yajnik, Ph.D.  Global Head of Academic Partnerships and External Innovation  Global Head of Academic Partnerships and External Innovation, NIBR  American